Abstract：Objective To analyze the clinical effect and safety of Methylprednisolone in the treatment of acute multiple sclerosis. Methods A total of 94 patients with acute multiple sclerosis admitted to our hospital from January 2018 to August 2019 were selected as the research subjects.They were divided into the reference group (n=47) and the study group (n=47) by the random number table method.Dexamethasone combined with Methylprednisolone treatment was applied in the reference group, 20 mg of Dexamethasone dissolved in 500 ml of 0.9% sodium chloride was injected intravenously for 5 days, followed by oral administration of 10 mg of Methylprednisolone daily for 90 days.In the study group, patients were treated with Methylprednisolone, 1000 mg of Methylprednisolone dissolved in 500 ml of 0.9%sodium chloride was injected intravenously for 5 days, followed by oral administration of 60 mg of Methylprednisolone daily for 90 days.The levels of CD4+, CD8+, CD4+/CD8+ and the total incidence rate of adverse reaction were compared between the two groups. Results There was no significant difference in the level of CD4+ between the two groups after treatment (P＞0.05).The level of CD8+ in the study group after treatment was higher than that of the reference group,and the difference was statistically significant (P＜0.05).There was no significant difference in the level of CD4+/CD8+between the two groups after treatment (P＞0.05).The total incidence rate of adverse reaction in the study group was lower than that of the reference group, and the difference was statistically significant (P＜0.05). Conclusion Methylprednisolone applied in the treatment of acute multiple sclerosis can effectively regulate the balance of T lymphocyte subsets and reduce patients′ adverse reactions, which is worthy of promotion.
京公网安备 11010502046607号